ABUS vs CSGP · P/E 5.4, rev $6.2M vs P/E 484, rev $2.74B
Arbutus Biopharma Corp (ABUS) versus CoStar Group Inc (CSGP) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
CoStar Group Inc (CSGP) is a real estate services company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CSGP revenue for 2024-12-31 was $2.74B. Net income was $138.7M. Revenue was up 11.5% from 2023-12-31 to 2024-12-31. CSGP currently screens at market cap $13.84B and trailing P/E 484.1.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CSGP currently screens at market cap $13.84B and trailing P/E 484.1.
Not investment advice. Open the ABUS and CSGP stock pages for the full models.
Not investment advice.